PACRITINIB for Myeloproliferative neoplasm: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 365 adverse event reports in the FDA FAERS database where PACRITINIB was used for Myeloproliferative neoplasm.
Most Reported Side Effects for PACRITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 536 | 20.9% | 13 | 64 |
| Off label use | 459 | 17.9% | 33 | 56 |
| Fatigue | 320 | 12.5% | 9 | 40 |
| Product dose omission issue | 279 | 10.9% | 6 | 60 |
| Death | 261 | 10.2% | 260 | 23 |
| Nausea | 246 | 9.6% | 8 | 36 |
| Platelet count decreased | 237 | 9.3% | 4 | 42 |
| Haemoglobin decreased | 171 | 6.7% | 5 | 43 |
| Asthenia | 119 | 4.6% | 5 | 22 |
| Drug ineffective | 98 | 3.8% | 2 | 9 |
| Dizziness | 96 | 3.8% | 4 | 12 |
| Splenomegaly | 84 | 3.3% | 2 | 11 |
| Transfusion | 83 | 3.2% | 1 | 23 |
| Constipation | 75 | 2.9% | 2 | 9 |
| Dyspnoea | 75 | 2.9% | 3 | 23 |
Other Indications for PACRITINIB
Myelofibrosis (1,586)
Product used for unknown indication (154)
Myelodysplastic syndrome (112)
Polycythaemia vera (112)
Essential thrombocythaemia (66)
Acute myeloid leukaemia (21)
Thrombocytopenia (21)
Marrow hyperplasia (17)
Chronic myelomonocytic leukaemia (13)
Immune thrombocytopenia (12)
Other Drugs Used for Myeloproliferative neoplasm
RUXOLITINIB (2,982)
LENALIDOMIDE (163)
HYDROXYUREA (162)
FEDRATINIB (146)
AZACITIDINE (99)
VENETOCLAX (94)
PEGINTERFERON ALFA-2A (75)
IMATINIB (71)
THALIDOMIDE (56)
ROPEGINTERFERON ALFA-2B-NJFT (54)